Product Website: www.lynparzahcp.com

Production Information: 

LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:

For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.

For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.

In patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negativemetastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine treatment. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.

NDC Code: 00310-0679-12 TAB 150 mg 120 count bottle

Companion Diagnostic: YES   

REMs: NO 

Limited Distribution: YES  

Manufacturer Reimbursement Assistance:

Patient Assistance (844) 275-2360 or www.myaccess360.com.  If there are financial barriers to fulfilling this prescription, www.astrazeneca-us.com/medicines/Affordability.html may be able to help.

Online Information:

Direct to patient nurse/clinical support program:

Additional products/supplies for patients:

Professional educational materials available from your sales specialist:

Online Information: